CSTL NASDAQ
Castle Biosciences, Inc.
1W: -0.7%
1M: +6.4%
3M: +46.9%
YTD: -7.7%
1Y: +54.5%
3Y: +117.0%
5Y: -50.9%
$35.56
+0.30 (+0.87%)
Weekly Expected Move ±5.0%
$32
$34
$36
$37
$39
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#31
of 92
Medical - Diagnostics & Research
Technical Signal Map
8 Bullish
3 Neutral
8 Bearish
CSTL
$1.1B
Castle Biosciences, Inc.
BULLISH
+82
GRAL
$6.2B
GRAIL Inc.
BULLISH
+91
CDNA
$3.5B
CareDx, Inc
BULLISH
+91
MYGN
$430M
Myriad Genetics, Inc.
BULLISH
+78
VCYT
$3.7B
Veracyte, Inc.
BULLISH
+66
FLGT
$610M
Fulgent Genetics, Inc.
BULLISH
+52
QGEN
$9.2B
Qiagen N.V.
BULLISH
+49
PSNL
$1.7B
Personalis, Inc.
LEAN BULL
+18
NEO
$470M
NeoGenomics, Inc.
NEUTRAL
+6
BLLN
$4.9B
BillionToOne, Inc.
NEUTRAL
-2
OPK
$1.2B
OPKO Health, Inc.
NEUTRAL
-8
MRCHF
$1.2B
H.U. Group Holdings, Inc.
BEARISH
-53
SKHCF
$6.4B
Sonic Healthcare Limited
BEARISH
-60
RDNT
$5.5B
RadNet, Inc.
BEARISH
-75
SHC
$5.2B
Sotera Health Company
BEARISH
-84
DSRLF
$4.2B
DiaSorin S.p.A.
BEARISH
-87
WGS
$2.2B
GeneDx Holdings Corp.
BEARISH
-87
VIMGF
$1.5B
Vimian Group AB (publ)
BEARISH
-91
IDGXF
$310M
Integrated Diagnostics Holdings plc
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| CSTL Castle Biosciences, Inc. | $1.1B | -53.9 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 54.5 |
| GRAL GRAIL Inc. | $6.2B | -14.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 130.8 |
| CDNA CareDx, Inc | $3.5B | 31.2 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 347.7 |
| MYGN Myriad Genetics, Inc. | $430M | -3.8 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -41.3 |
| VCYT Veracyte, Inc. | $3.7B | 31.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 26.5 |
| FLGT Fulgent Genetics, Inc. | $610M | -7.6 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | BULLISH | -8.6 |
| QGEN Qiagen N.V. | $9.2B | 22.9 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | -3.4 |
| PSNL Personalis, Inc. | $1.7B | -14.9 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | LEAN BULL | 135.6 |
| NEO NeoGenomics, Inc. | $470M | -9.3 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | NEUTRAL | 111.8 |
| BLLN BillionToOne, Inc. | $4.9B | 153.5 | 6.0 | 25.2 | 7.4 | — | 4 | NEUTRAL | — |
| OPK OPKO Health, Inc. | $1.2B | -16.4 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | NEUTRAL | 0.7 |
| MRCHF H.U. Group Holdings, Inc. | $1.2B | 20.0 | 5.0 | 2.3 | 2.0 | 2.3 | 9 | BEARISH | -11.6 |
| SKHCF Sonic Healthcare Limited | $6.4B | 15.0 | 13.8 | 22.2 | 6.2 | 21.4 | 5 | BEARISH | -12.3 |
| RDNT RadNet, Inc. | $5.5B | -262.4 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BEARISH | -10.3 |
| SHC Sotera Health Company | $5.2B | 31.8 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | BEARISH | 12.5 |
| DSRLF DiaSorin S.p.A. | $4.2B | 23.3 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BEARISH | -10.9 |
| WGS GeneDx Holdings Corp. | $2.2B | -20.1 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -35.6 |
| VIMGF Vimian Group AB (publ) | $1.5B | 44.8 | 5.2 | 5.9 | 6.9 | 10.8 | 6 | BEARISH | -8.0 |
| IDGXF Integrated Diagnostics Holdings plc | $310M | 11.0 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BEARISH | 11.2 |
| CSTL Castle Biosciences, Inc. | $1.1B | -53.9 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 54.5 |
| AMPH Amphastar Pharmaceuticals, Inc. | $1.1B | 14.6 | 10.3 | 7.5 | 16.5 | 1.4 | 6 | LEAN BULL | -5.8 |
| STAA STAAR Surgical Company | $1.1B | 280.9 | 1.1 | 3.5 | 8.6 | 51.3 | 5 | LEAN BEAR | -17.3 |
| RKAGY RHÃN-KLINIKUM Aktiengesellschaft | $1.1B | 22.5 | 2.8 | 3.1 | 2.1 | 2.5 | 6 | BEARISH | 10.7 |
| IRMD IRadimed Corporation | $1.1B | 46.9 | 23.5 | 50.1 | 25.5 | 11.2 | 6 | BEARISH | 22.2 |
| REPL Replimune Group, Inc. | $1.1B | -4.1 | -107.9 | -2853.5 | — | — | 1 | BEARISH | 210.4 |
| CVSGF CVS Group plc | $1.1B | 45.6 | 16.0 | 17.2 | 2.7 | 49.6 | 6 | BEARISH | 1.8 |
| LYPHF Luye Pharma Group Ltd. | $1.1B | 9.1 | 7.6 | 13.0 | 13.0 | -1.2 | 4 | BEARISH | 0.8 |
| TNDM Tandem Diabetes Care, Inc. | $1.1B | -17.8 | -48.0 | -8.2 | -8.3 | -7.1 | 4 | BEARISH | 33.0 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.3 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | BEARISH | -28.6 |
| GDRX GoodRx Holdings, Inc. | $1.1B | 62.4 | 2.5 | 3.5 | 4.3 | -1.8 | 6 | BEARISH | -34.8 |
| LFTSF LifeTech Scientific Corporation | $1.0B | 88.1 | 7.3 | 6.9 | -5.7 | 9.2 | 4 | BEARISH | 0.0 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.1B | -12.5 | -25.8 | -768.9 | — | — | 2 | BEARISH | 134.7 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.2B | -5.7 | -41.0 | 583.9 | — | — | 2 | BEARISH | 6.1 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $1.1B | 18.4 | 4.2 | -0.8 | 19.4 | 33.4 | 7 | BEARISH | 21.7 |
| CMOPF Cosmo Pharmaceuticals N.V. | $1.1B | -148.1 | 9.2 | 10.2 | -9.5 | -1.7 | 3 | BEARISH | -22.4 |
| TTALF Terveystalo Oyj | $1.1B | 13.7 | 12.6 | 7.6 | 4.7 | -7.9 | 4 | BEARISH | -30.9 |
| ASCLF Ascletis Pharma Inc. | $1.1B | -11.8 | -38.0 | -12387.1 | — | -95.5 | 2 | BEARISH | -14.8 |
| AORT Artivion, Inc. | $1.1B | -374.3 | -0.7 | -3.4 | -10.7 | 16.4 | 4 | BEARISH | -45.7 |
| HROW Harrow Health, Inc. | $1.1B | -30.7 | -114.8 | 1.9 | -24.4 | 21.1 | 5 | BEARISH | -37.0 |
| TRAX First Tracks Biotherapeutics Inc | $1.2B | — | — | — | — | — | — | BEARISH | — |
| CSTL Castle Biosciences, Inc. | $1.1B | -53.9 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 54.5 |
| ONTTF Oxford Nanopore Technologies plc | $3.0B | -14.0 | -52.9 | -79.5 | -41.1 | 33.0 | 3 | BULLISH | 39.5 |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.2B | -14.8 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 151.6 |
| ABSI Absci Corporation | $1.9B | -13.8 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 253.7 |
| AMN AMN Healthcare Services, Inc. | $1.4B | 13.6 | 15.6 | 8.9 | 3.1 | 24.0 | 8 | BULLISH | 83.6 |
| HSTM HealthStream, Inc. | $900M | 43.1 | 6.0 | 6.5 | 8.0 | 8.8 | 8 | BULLISH | 12.3 |
| SDEV Stablecoin Development Corp. | $380M | — | — | — | — | — | — | BULLISH | — |
| HNGE Hinge Health, Inc. | $7.6B | 72.5 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 100.3 |
| IOVA Iovance Biotherapeutics, Inc. | $6.3B | -20.3 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | BULLISH | 543.4 |
| GRAL GRAIL Inc. | $6.2B | -14.7 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 130.8 |
| LGND Ligand Pharmaceuticals Incorporated | $6.1B | 30.3 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 69.2 |
| KOD Kodiak Sciences Inc. | $5.9B | -22.5 | -368.4 | -630.1 | — | — | 1 | BULLISH | 499.3 |
| MANE Veradermics, Incorporated | $4.9B | — | — | — | — | — | — | BULLISH | — |
| ABCL AbCellera Biologics Inc. | $4.2B | -25.4 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | BULLISH | 130.5 |
| CDNA CareDx, Inc | $3.5B | 31.2 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 347.7 |
| PGEN Precigen, Inc. | $3.0B | -7.5 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BULLISH | 155.7 |
| UFPT UFP Technologies, Inc. | $2.3B | 32.1 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | BULLISH | 50.7 |
| FTRE Fortrea Holdings Inc. | $1.9B | -21.5 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 110.1 |
| AZTA Azenta, Inc. | $1.8B | -14.1 | -7.7 | -1.4 | 1.5 | 1.5 | 4 | BULLISH | 22.7 |
| NVAX Novavax, Inc. | $1.7B | -6.9 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BULLISH | 10.1 |
| NUTX Nutex Health, Inc. | $1.5B | 8.3 | 49.2 | 53.9 | 31.2 | 6.9 | 7 | BULLISH | 107.4 |
| CERT Certara, Inc. | $1.5B | -21.1 | -6.7 | 0.6 | -59.3 | 0.7 | 6 | BULLISH | -30.0 |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 492.5 | -1.3 | 7.7 | 0.7 | 17.1 | 5 | BULLISH | -2.1 |
| CTKB Cytek Biosciences, Inc. | $760M | -9.4 | -23.0 | -40.8 | -25.3 | 5.4 | 3 | BULLISH | 62.6 |
| KHTRF Knight Therapeutics Inc. | $730M | 70.2 | 1.9 | 2.6 | -2.3 | 42.4 | 8 | BULLISH | 69.0 |
| MASS 908 Devices Inc. | $520M | -13.6 | -25.1 | -103.8 | -74.0 | 4.6 | 5 | BULLISH | 41.2 |
| TKNO Alpha Teknova, Inc. | $480M | -28.5 | -24.2 | -17.2 | -26.0 | 12.3 | 4 | BULLISH | 41.1 |
| RCEL Avita Medical Inc. | $320M | -8.8 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 142.3 |
| INCPF InnoCare Pharma Limited | $2.8B | 22.4 | 12.6 | 127.0 | 23.1 | 108.5 | 5 | BULLISH | -43.2 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | -4.0 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -19.2 |
| AHG Akso Health Group | $980M | -4.4 | -50.1 | -44.9 | -546.5 | 22.7 | 4 | BULLISH | -31.6 |
| PACB Pacific Biosciences of California, Inc. | $790M | -5.9 | -929.3 | -29.4 | -114.7 | 2.0 | 2 | BULLISH | 84.1 |
| QSI Quantum-Si incorporated | $310M | -3.3 | -49.1 | -121.8 | -6841.3 | -53.0 | 3 | BULLISH | 6.2 |
| AGEN Agenus Inc. | $350M | 3.1 | -33.2 | -20.4 | -1.6 | 30.5 | 6 | BULLISH | 114.4 |
| OABIW OmniAb, Inc. | $2.5B | -13.5 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -9.3 |
| DNA Ginkgo Bioworks Holdings, Inc. | $810M | -2.5 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BULLISH | -15.9 |
| YDES YD Bio Limited Ordinary Shares | $570M | — | — | — | — | — | — | BULLISH | -54.7 |
| DMAC DiaMedica Therapeutics Inc. | $440M | -11.4 | -114.6 | 616.3 | — | — | 2 | BULLISH | 20.0 |
| MYGN Myriad Genetics, Inc. | $430M | -3.8 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -41.3 |
| HYPMY Hypera S.A. | $3.4B | 9.4 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BULLISH | 20.1 |
| BVNKF Bavarian Nordic A/S | $2.6B | 11.0 | 12.2 | 13.3 | 36.0 | -2.6 | 7 | BULLISH | -7.3 |
| DGWPF Drägerwerk AG & Co. KGaA | $1.9B | 12.8 | 10.9 | 9.8 | 3.4 | 6.5 | 9 | BULLISH | 79.5 |
| COGZF Cogstate Limited | $400M | 32.9 | 49.6 | 94.6 | 22.4 | 3.7 | 6 | BULLISH | 85.7 |
| BLFS BioLife Solutions, Inc. | $1.8B | 36.1 | 13.2 | 13.2 | 158.4 | 34.4 | 6 | BULLISH | 42.8 |
| SENS Senseonics Holdings, Inc. | $410M | -4.4 | -118.2 | -901.4 | -253.4 | 79.0 | 3 | BULLISH | 19.6 |
| BRKR Bruker Corporation | $9.6B | -90.5 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 82.3 |
| RMYHY Ramsay Health Care Limited | $8.9B | 40.0 | 7.2 | 12.3 | 1.8 | 14.8 | 5 | BULLISH | 76.2 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 40.8 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 95.6 |
| ANSLY Ansell Limited | $4.4B | 21.2 | 16.0 | 14.8 | 10.8 | 27.0 | 7 | BULLISH | 37.5 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | BULLISH | 22.9 |
| VCYT Veracyte, Inc. | $3.7B | 31.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 26.5 |
| CZMWF Carl Zeiss Meditec AG | $3.3B | 18.7 | 5.6 | 4.8 | 9.8 | 47.0 | 7 | BULLISH | -23.0 |
| ALMR Alamar Biosciences, Inc. | $2.4B | — | — | — | — | — | — | BULLISH | — |
| BFLY Butterfly Network, Inc. | $2.4B | -30.9 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | BULLISH | 370.0 |
| TCNNF Trulieve Cannabis Corp. | $2.4B | -26.5 | -47.6 | -20.5 | -149.8 | -3.9 | 5 | BULLISH | 37.6 |
| SAEYY Redcare Pharmacy N.V. | $1.6B | -33.6 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -4.7 |
| KMTS Kestra Medical Technologies, Ltd. | $1.6B | -10.3 | -56.6 | -96.8 | -135.6 | 452.0 | 4 | BULLISH | 13.6 |
| SSMXF Sysmex Corporation | $7.5B | 28.5 | 7.3 | 9.3 | 1.3 | -1.1 | 5 | BULLISH | 2.9 |
| DRTSW Alpha Tau Medical Ltd. | $1.6B | -14.2 | -141.7 | -17.1 | — | — | 3 | BULLISH | 1253.3 |
| MDRX Veradigm Inc. | $830M | -7.3 | 4.3 | 7.0 | 6.2 | -39.7 | 5 | BULLISH | 4.3 |
| TTRX Turn Therapeutics Inc. | $400M | -45.7 | -952.4 | 115.0 | — | — | 2 | BULLISH | — |
| OBIO Orchestra BioMed Holdings, Inc. | $360M | -6.0 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | BULLISH | 133.3 |
| EMBC Embecta Corp. | $340M | 3.8 | -13.6 | 26.3 | 7.8 | -7.6 | 5 | BULLISH | -61.1 |
| DOCS Doximity, Inc. | $5.2B | 31.4 | 19.3 | 79.3 | 13.1 | 13.1 | 6 | BULLISH | -60.5 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 15.3 | 11.8 | 10.2 | 3.2 | 8.7 | 6 | BULLISH | -12.2 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $440M | 72.0 | 4.7 | 0.9 | 4.4 | -3.1 | 4 | BULLISH | inf |
| RGC Regencell Bioscience Holdings Limited | $3.4B | -480.3 | -156.4 | 957.8 | — | 100.0 | 2 | BULLISH | -56.9 |
| VMD Viemed Healthcare, Inc. | $350M | 24.2 | 10.2 | 11.8 | 3.5 | 25.2 | 4 | BULLISH | 31.8 |
| DMTRF 3-D Matrix, Ltd. | $350M | 13.8 | 92.3 | 29.3 | 50.9 | 56.9 | 5 | BULLISH | 80.0 |
| CON Concentra Group Holdings Parent, Inc. | $4.6B | 23.0 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 71.6 |
| ADPT Adaptive Biotechnologies Corporation | $4.5B | -69.6 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BULLISH | 94.7 |
| LKFT Lakefront Biotherapeutics N.V. | $1.9B | — | — | — | — | — | — | BULLISH | — |
| XERS Xeris Biopharma Holdings, Inc. | $1.6B | -93.5 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 13.4 |
| RIGL Rigel Pharmaceuticals, Inc. | $870M | 2.7 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 67.4 |
| GYRE Gyre Therapeutics, Inc. | $790M | -35.7 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | BULLISH | -6.2 |
| SY So-Young International Inc. | $360M | -10.0 | -15.7 | -22.3 | -11.4 | 14.1 | 4 | BULLISH | -27.8 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $6.5B | 18.8 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BULLISH | -30.0 |
| SGFEF Siegfried Holding AG | $3.9B | 17.9 | 34.3 | 18.4 | 10.8 | 3.9 | 6 | BULLISH | -22.9 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.5 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | BULLISH | -4.5 |
| PPTDF PeptiDream Inc. | $940M | -38.3 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BULLISH | -34.3 |
| SOPH SOPHiA GENETICS S.A. | $680M | -7.0 | -101.2 | -155.2 | -95.9 | 23.6 | 3 | BULLISH | 81.3 |
| FLGT Fulgent Genetics, Inc. | $610M | -7.6 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | BULLISH | -8.6 |
| SHWGF Shandong Weigao Group Medical Polymer Company Limited | $1.9B | 9.2 | 14.0 | 15.7 | 11.3 | -0.2 | 4 | BULLISH | -44.7 |
| CASBF CanSino Biologics Inc. | $1.6B | 523.4 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BULLISH | -29.6 |
| ADMA ADMA Biologics, Inc. | $2.2B | 13.5 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -35.4 |
| QGEN Qiagen N.V. | $9.2B | 22.9 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | -3.4 |
| SGHT Sight Sciences, Inc. | $460M | -15.3 | -48.4 | -145.7 | -19.0 | 9.3 | 4 | BULLISH | 154.6 |
| SNPHF Santen Pharmaceutical Co., Ltd. | $4.2B | 13.8 | 12.8 | 14.4 | 19.2 | -2.3 | 7 | BULLISH | 14.0 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.8 | 1.9 | 8.4 | 6.6 | -8.6 | 7 | BULLISH | 84.1 |
| FDMDF 4DMedical Limited | $1.8B | -11.0 | -194.6 | 65.5 | -1194.8 | 188.6 | 5 | BULLISH | 129.0 |
| CLCGY Clicks Group Limited | $3.0B | 14.9 | 109.2 | 70.8 | 5.7 | 14.5 | 9 | BULLISH | -37.3 |
| MAHLY MediPal Holdings Corporation | $3.9B | 12.9 | 6.8 | 9.6 | 0.6 | 5.4 | 7 | BULLISH | 4.5 |
| DRTS Alpha Tau Medical Ltd | $1.3B | -14.2 | -141.7 | -17.1 | — | — | 3 | BULLISH | 238.0 |
| CSSPF NIOX Group Plc | $380M | 40.0 | 16.6 | 23.1 | 24.6 | 27.2 | 6 | BULLISH | -2.3 |
| EKTAF Elekta AB (publ) | $2.0B | -54.7 | -6.5 | 6.2 | -18.2 | -7.5 | 2 | BULLISH | 3.5 |
| WILYY Demant A/S | $9.9B | 40.7 | 38.1 | 21.5 | 9.1 | 8.7 | 5 | BULLISH | 27.3 |
| BRCTF BioArctic AB (publ) | $3.3B | 256.5 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BULLISH | 17.6 |
| SYRE Spyre Therapeutics, Inc. | $8.1B | -47.8 | -23.0 | 359.8 | — | — | 3 | BULLISH | 466.2 |
| STTK Shattuck Labs, Inc. | $610M | -13.2 | -39.2 | -29.3 | — | -66.6 | 4 | BULLISH | 182.8 |
| HIMS Hims & Hers Health, Inc. | $6.5B | -47.5 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BULLISH | -48.5 |
| TCHBF Tecan Group AG | $3.4B | -25.2 | -4.2 | 8.0 | 2.9 | -15.6 | 4 | BULLISH | 35.5 |
| MLAB Mesa Laboratories, Inc. | $740M | 154.1 | 3.9 | 3.2 | -6.5 | 3.4 | 8 | BULLISH | 88.5 |
| HAE Haemonetics Corporation | $4.8B | 50.8 | 12.0 | 10.4 | -5.8 | -2.0 | 6 | BULLISH | 114.5 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | BULLISH | 25.3 |
| HCM HUTCHMED (China) Limited | $2.5B | 155.0 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BULLISH | -11.0 |
| INSP Inspire Medical Systems, Inc. | $2.0B | 15.0 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | BULLISH | -3.3 |
| PRGO Perrigo Company plc | $2.0B | -1.1 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | LEAN BULL | -35.2 |
| NTLA Intellia Therapeutics, Inc. | $1.7B | -3.6 | -55.4 | -92.1 | -1392.3 | 12.6 | 4 | LEAN BULL | -34.6 |
| PAHC Phibro Animal Health Corporation | $1.5B | 15.1 | 29.7 | 13.2 | 5.5 | 17.1 | 7 | LEAN BULL | -8.5 |
| SI Shoulder Innovations, Inc. | $390M | -11.1 | -28.2 | -69.1 | -59.1 | — | 1 | LEAN BULL | 58.1 |
| ENTA Enanta Pharmaceuticals, Inc. | $380M | -5.4 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BULL | 22.1 |
| RADLY Raia Drogasil S.A. | $6.6B | 25.1 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | LEAN BULL | 11.9 |
| NHC National HealthCare Corporation | $3.6B | 25.2 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | LEAN BULL | 82.7 |
| VIR Vir Biotechnology, Inc. | $1.9B | -6.0 | -26.1 | -38.9 | 33.5 | 1495.9 | 4 | LEAN BULL | 96.0 |
| SZUKF Suzuken Co., Ltd. | $2.0B | 9.4 | 9.3 | 9.3 | 1.2 | 4.2 | 3 | LEAN BULL | 4.8 |
| CV CapsoVision, Inc. | $310M | -9.8 | -226.6 | -73.0 | -205.4 | — | 2 | LEAN BULL | 31.3 |
| SMTI Sanara MedTech Inc. | $320M | -9.4 | -147.7 | 19.8 | -1.6 | 12.9 | 5 | LEAN BULL | 13.2 |
| SMDPY Sumitomo Pharma Co., Ltd. | $4.6B | 5.8 | 46.9 | 11.7 | -0.8 | 15.2 | 5 | LEAN BULL | -6.1 |
| PSNL Personalis, Inc. | $1.7B | -14.9 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | LEAN BULL | 135.6 |
| NWKHY Netcare Limited | $1.2B | 11.8 | 31.4 | 23.7 | 6.7 | 12.6 | 7 | LEAN BULL | 45.8 |
| MNKD MannKind Corporation | $1.2B | -27.2 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | LEAN BULL | -29.4 |
| CNVVF ConvaTec Group Plc | $5.7B | 45.2 | 21.9 | 19.2 | 4.4 | 10.0 | 6 | LEAN BULL | 0.3 |
| GNNDY GN Store Nord A/S | $2.3B | -27.4 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | LEAN BULL | -6.1 |
| EBS Emergent BioSolutions Inc. | $330M | -1.8 | -40.3 | -5.5 | -76.9 | -9.6 | 5 | LEAN BULL | -31.0 |
| NHNKY Nihon Kohden Corporation | $3.2B | 18.7 | 8.1 | 8.7 | 11.4 | 5.2 | 8 | LEAN BULL | -17.1 |
| AMBBY Ambu A/S | $2.9B | 35.3 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | LEAN BULL | -25.9 |
| AMPH Amphastar Pharmaceuticals, Inc. | $1.1B | 14.6 | 10.3 | 7.5 | 16.5 | 1.4 | 6 | LEAN BULL | -5.8 |
| WHTCF WELL Health Technologies Corp. | $790M | 170.4 | 0.5 | 5.4 | -2.7 | 38.6 | 6 | LEAN BULL | -20.0 |
| NNCSF Nanosonics Limited | $610M | 48.9 | 19.3 | 35.7 | 8.1 | 19.0 | 7 | LEAN BULL | -28.4 |
| VCEL Vericel Corporation | $2.1B | 83.6 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | LEAN BULL | 29.9 |
| MAZE Maze Therapeutics, Inc. | $1.5B | -9.6 | -37.3 | -112.3 | — | — | 3 | NEUTRAL | 2.4 |
| CRSP CRISPR Therapeutics AG | $5.3B | -11.6 | -26.1 | -253.2 | -895.3 | -62.7 | 2 | NEUTRAL | -16.2 |
| IOBCF Ion Beam Applications S.A. | $530M | 18.3 | 39.6 | 26.8 | 2.9 | 41.2 | 5 | NEUTRAL | 43.7 |
| CAPR Capricor Therapeutics, Inc. | $510M | -3.7 | -73.7 | -107.5 | — | -100.0 | 3 | NEUTRAL | 14.4 |
| PBYI Puma Biotechnology, Inc. | $480M | 17.7 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | NEUTRAL | 80.5 |
| CAI Caris Life Sciences, Inc. | $8.0B | 76.1 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | NEUTRAL | -6.7 |
| ATEC Alphatec Holdings, Inc. | $1.5B | -13.9 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | NEUTRAL | -28.2 |
| NEO NeoGenomics, Inc. | $470M | -9.3 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | NEUTRAL | 111.8 |
| PNTG The Pennant Group, Inc. | $1.4B | 41.7 | 9.6 | 5.5 | 3.0 | 37.9 | 6 | NEUTRAL | 61.7 |
| ANL Adlai Nortye Ltd. | $800M | -7.7 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | NEUTRAL | 738.3 |
| ESALF Eisai Co., Ltd. | $8.6B | 31.3 | 3.7 | 3.2 | 7.8 | 242.3 | 6 | NEUTRAL | -11.6 |
| BCHMF Bachem Holding AG | $6.8B | 39.8 | 20.6 | 17.5 | 15.4 | 24.3 | 6 | NEUTRAL | 48.1 |
| HLUBF H. Lundbeck A/S | $6.8B | 11.2 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | NEUTRAL | 17.0 |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 27.3 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | NEUTRAL | 16.4 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 19.9 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| CHSYF China Medical System Holdings Limited | $3.8B | 14.6 | 18.7 | 19.8 | 21.9 | 0.7 | 5 | NEUTRAL | 16.3 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.6 | 11.4 | 3.2 | 93.0 | 8.4 | 6 | NEUTRAL | 5.3 |
| ARSUF Fagron N.V. | $2.0B | 18.0 | 33.2 | 20.7 | 8.4 | 25.8 | 5 | NEUTRAL | 17.0 |
| SAFLY Safilo Group S.p.A. | $1.4B | 14.3 | 22.4 | 19.9 | 8.7 | -4.8 | 7 | NEUTRAL | 40.1 |
| OMER Omeros Corporation | $1.4B | 9.7 | -89.2 | 71.8 | 46.4 | — | 5 | NEUTRAL | 349.5 |
| CAIHF CPBIO Holding Company Limited | $830M | 10.5 | 10.0 | 8.1 | 3.4 | 73.4 | 8 | NEUTRAL | 282.1 |
| VREX Varex Imaging Corporation | $780M | 35.2 | 4.6 | 7.6 | 7.5 | 5.3 | 6 | NEUTRAL | 50.9 |
| SOLTF Nxera Pharma Co., Ltd. | $720M | -14.1 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | NEUTRAL | 22.2 |
| ANIP ANI Pharmaceuticals, Inc. | $1.6B | 14.9 | 20.0 | 20.7 | 9.3 | 30.9 | 7 | NEUTRAL | -20.0 |
| ARRJF Arjo AB (publ) | $790M | 19.0 | 5.0 | 4.3 | 4.5 | -3.5 | 6 | NEUTRAL | -16.9 |
| OPHLF Ono Pharmaceutical Co., Ltd. | $7.0B | 14.1 | 8.6 | 10.5 | 0.7 | 6.5 | 7 | NEUTRAL | 44.4 |
| INDV Indivior Pharmaceuticals Inc | $4.5B | 12.6 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | NEUTRAL | 52.2 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 16.0 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 56.8 |
| BLLN BillionToOne, Inc. | $4.9B | 153.5 | 6.0 | 25.2 | 7.4 | — | 4 | NEUTRAL | — |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.9 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | NEUTRAL | -7.5 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | NEUTRAL | -31.5 |
| OMCL Omnicell, Inc. | $1.5B | 39.3 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | NEUTRAL | 12.2 |
| PCRX Pacira BioSciences, Inc. | $990M | 71.6 | 2.0 | 1.8 | 2.4 | 5.7 | 8 | NEUTRAL | -0.2 |
| HTFL Heartflow, Inc. Common Stock | $4.2B | -34.7 | -42.3 | -39.8 | -24.6 | — | 2 | NEUTRAL | 37.3 |
| VSTM Verastem, Inc. | $680M | -3.1 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | NEUTRAL | -12.5 |
| SHPMF Shanghai Pharmaceuticals Holding Co., Ltd | $8.5B | 12.6 | 6.2 | 6.5 | 2.9 | 4.0 | 5 | NEUTRAL | -4.6 |
| ASTH Astrana Health, Inc. | $1.8B | 43.4 | 5.1 | 4.7 | 2.0 | 58.9 | 5 | NEUTRAL | 27.4 |
| EVOTF Evotec SE | $1.2B | -2.6 | -26.1 | -14.9 | -32.5 | -7.7 | 2 | NEUTRAL | -8.1 |
| OPK OPKO Health, Inc. | $1.2B | -16.4 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | NEUTRAL | 0.7 |
| CSWYF China Shineway Pharmaceutical Group Limited | $760M | 6.0 | 21.7 | 50.7 | 21.6 | 277.6 | 4 | NEUTRAL | -12.7 |
| ALVOW Alvotech | $2.4B | -9.3 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | NEUTRAL | -81.7 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -2.6 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | NEUTRAL | -49.2 |
| LTGHY Life Healthcare Group Holdings Limited | $1.0B | 2.4 | 52.6 | 6.9 | 6.2 | 19.4 | 7 | LEAN BEAR | 3.7 |
| WAY Waystar Holding Corp. | $4.8B | 34.5 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | LEAN BEAR | -33.2 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.1B | 113.9 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | LEAN BEAR | 27.3 |
| STLN Starling Oncology, Inc. | $630M | — | — | — | — | — | — | LEAN BEAR | — |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 17.4 | 12.3 | 19.3 | 16.7 | -9.6 | 4 | LEAN BEAR | 0.0 |
| OSSFF Embla Medical hf. | $1.9B | 18.9 | 10.7 | 7.7 | 11.3 | 11.7 | 7 | LEAN BEAR | -5.6 |
| SGIPF Sugi Holdings Co.,Ltd. | $1.8B | 14.6 | 8.8 | 9.6 | 3.6 | -12.7 | 5 | LEAN BEAR | -41.7 |
| PRVA Privia Health Group, Inc. | $2.6B | 90.3 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | LEAN BEAR | -18.7 |
| NVCT Nuvectis Pharma, Inc. | $580M | -16.7 | -214.6 | 174.4 | — | — | 1 | LEAN BEAR | 261.7 |
| PACS PACS Group, Inc. | $6.8B | 25.2 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | LEAN BEAR | 205.7 |
| ATRC AtriCure, Inc. | $2.8B | 259.8 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | LEAN BEAR | 61.1 |
| MD Pediatrix Medical Group, Inc. | $2.1B | 12.3 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | LEAN BEAR | 52.9 |
| XNCR Xencor, Inc. | $1.8B | -11.4 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | LEAN BEAR | 110.0 |
| PROK ProKidney Corp. | $580M | -3.0 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | LEAN BEAR | -33.9 |
| OSCR Oscar Health, Inc. | $8.0B | 18.1 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | LEAN BEAR | 63.7 |
| TGTX TG Therapeutics, Inc. | $8.3B | 17.8 | 100.3 | 73.5 | 3.2 | 76.1 | 5 | LEAN BEAR | 48.5 |
| KYKOF Kyowa Kirin Co., Ltd. | $7.3B | 14.4 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | LEAN BEAR | -18.0 |
| TNGX Tango Therapeutics, Inc. | $3.8B | -27.3 | -21.3 | -253.2 | — | 121.5 | 3 | LEAN BEAR | 191.2 |
| CLOV Clover Health Investments, Corp. | $2.3B | -108.1 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | LEAN BEAR | 67.2 |
| MDXG MiMedx Group, Inc. | $670M | 114.8 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | LEAN BEAR | -32.8 |
| CSPHF CStone Pharmaceuticals | $1.2B | -17.9 | -74.4 | -553.0 | -123.0 | -36.4 | 4 | LEAN BEAR | -24.5 |
| GNFTF Genfit S.a. | $790M | -4.5 | -575.3 | -453.0 | -124.0 | 1.4 | 4 | LEAN BEAR | 323.4 |
| BOEUF Bonesupport Holding AB (publ) | $1.5B | 68.7 | 24.6 | 42.3 | 23.0 | 20.8 | 6 | LEAN BEAR | -26.5 |
| RLAY Relay Therapeutics, Inc. | $4.2B | -12.1 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | LEAN BEAR | 256.4 |
| STAA STAAR Surgical Company | $1.1B | 280.9 | 1.1 | 3.5 | 8.6 | 51.3 | 5 | LEAN BEAR | -17.3 |
| NPRRF Nipro Corporation | $1.5B | — | — | — | — | — | — | LEAN BEAR | 9.7 |
| LJUIF SSY Group Limited | $1.2B | 16.1 | 15.5 | 11.9 | 13.6 | -30.2 | 4 | LEAN BEAR | 0.0 |
| AONC American Oncology Network, Inc. | $320M | -15.9 | 5.6 | -14.7 | 0.3 | 37.5 | 6 | LEAN BEAR | 29.4 |
| BIOGY BioGaia AB (publ) | $1.3B | 33.2 | 30.7 | 52.8 | 23.4 | 9.5 | 6 | LEAN BEAR | 10.7 |
| TBPH Theravance Biopharma Inc | $880M | 16.0 | 20.9 | -7.2 | -28.5 | 35.1 | 7 | LEAN BEAR | 21.2 |
| KIDS OrthoPediatrics Corp. | $570M | -13.2 | -11.4 | -4.6 | -10.2 | 14.5 | 6 | LEAN BEAR | 20.3 |
| CLVSF CellaVision AB (publ) | $330M | 31.2 | 15.1 | 17.1 | 16.3 | -1.9 | 6 | LEAN BEAR | -27.4 |
| VKTX Viking Therapeutics, Inc. | $3.5B | -6.4 | -88.9 | 495.6 | — | — | 1 | LEAN BEAR | 9.4 |
| GRDN Guardian Pharmacy Services, Inc. | $2.7B | 40.4 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | LEAN BEAR | 74.1 |
| BVS Bioventus Inc. | $890M | 16.3 | 28.0 | 21.3 | 21.8 | 3.1 | 7 | LEAN BEAR | 95.7 |
| BBNX Beta Bionics, Inc. | $850M | -11.3 | -26.2 | -79.6 | -73.1 | 191.1 | 3 | LEAN BEAR | -6.2 |
| CURLF Curaleaf Holdings, Inc. | $2.6B | -72.5 | -4.2 | 0.5 | 3.7 | 2.4 | 7 | LEAN BEAR | 14.0 |
| CBLL CeriBell, Inc. | $900M | -13.5 | -43.9 | -263.7 | -68.6 | 69.3 | 3 | LEAN BEAR | 104.9 |
| MTHRY M3, Inc. | $7.3B | 25.5 | 13.1 | 17.9 | 8.6 | 25.0 | 6 | LEAN BEAR | -28.7 |
| BPMUF Basilea Pharmaceutica AG | $940M | 15.7 | 140.1 | 185.7 | 23.5 | 49.5 | 9 | LEAN BEAR | 12.6 |
| RKAGY RHÃN-KLINIKUM Aktiengesellschaft | $1.1B | 22.5 | 2.8 | 3.1 | 2.1 | 2.5 | 6 | BEARISH | 10.7 |
| ANNX Annexon, Inc. | $690M | -3.6 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 38.3 |
| PKBFF PeakBirch Commerce Inc. | $540M | -0.0 | -16609.0 | 16544.6 | -58.8 | -69.1 | 3 | BEARISH | 0.0 |
| NEOG Neogen Corporation | $2.6B | -366.0 | -0.4 | -0.6 | -5.0 | -2.7 | 6 | BEARISH | 109.5 |
| BHC Bausch Health Companies Inc. | $2.2B | -2.0 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BEARISH | -12.2 |
| SNBIF SanBio Company Limited | $1.3B | -19.7 | -50.0 | 1250.3 | — | — | 4 | BEARISH | 0.0 |
| REPL Replimune Group, Inc. | $1.1B | -4.1 | -107.9 | -2853.5 | — | — | 1 | BEARISH | 210.4 |
| IRMD IRadimed Corporation | $1.1B | 46.9 | 23.5 | 50.1 | 25.5 | 11.2 | 6 | BEARISH | 22.2 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $540M | 10.0 | 20.8 | 23.4 | 32.9 | 697.9 | 9 | BEARISH | 0.0 |
| SLS SELLAS Life Sciences Group, Inc. | $2.2B | -55.6 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 594.7 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $1.0B | 11.0 | 6.3 | -1.4 | 11.2 | 10.9 | 6 | BEARISH | -19.1 |
| BOIRF Boiron S.A. | $550M | 13.3 | 7.2 | 7.8 | 2.0 | -5.4 | 4 | BEARISH | 10.5 |
| AUNA Auna S.A. | $370M | -17.9 | 0.8 | 4.5 | 2.4 | 9.2 | 7 | BEARISH | -25.0 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $710M | 7.8 | 14.1 | 14.1 | 8.5 | 18.2 | 5 | BEARISH | -37.6 |
| CTNM Contineum Therapeutics, Inc. | $490M | -7.6 | -28.0 | -541.6 | — | — | 4 | BEARISH | 19.2 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 730.0 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | BEARISH | 11.2 |
| MCVEF Medicover AB (publ) | $4.1B | 40.2 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | BEARISH | 0.0 |
| TSMRF Tsumura & Co. | $1.7B | 9.1 | 9.1 | 7.0 | 10.5 | 6.9 | 3 | BEARISH | inf |
| STSEY Stratec SE | $1.7B | -542.5 | -0.2 | -0.2 | 7.0 | -4.8 | 4 | BEARISH | -17.8 |
| MDCLF MedinCell S.A. | $1.2B | -24.4 | 264.0 | 116.8 | -152.1 | 129.2 | 6 | BEARISH | 392.7 |
| AGYTF Allergy Therapeutics plc | $760M | -4.8 | -550.7 | -218.7 | -54.9 | 4.4 | 2 | BEARISH | 76.5 |
| CLHLF COLTENE Holding AG | $370M | 18.9 | 30.1 | 25.6 | 3.6 | -5.4 | 4 | BEARISH | 0.0 |
| TRSBF 3SBio Inc. | $5.4B | 4.1 | 50.1 | 99.1 | 25.3 | 66.8 | 7 | BEARISH | -38.6 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.3B | 12.7 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 47.2 |
| SHEZF Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | $690M | 70.6 | 2.8 | 2.7 | 7.0 | -0.3 | 6 | BEARISH | 0.0 |
| KMDA Kamada Ltd. | $480M | 21.7 | 8.4 | 11.0 | 16.9 | 13.2 | 7 | BEARISH | 21.5 |
| PBLS Parabilis Medicines, Inc. | $3.5B | — | — | — | — | — | — | BEARISH | — |
| GKOS Glaukos Corporation | $9.7B | -50.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BEARISH | 96.9 |
| HKMPY Hikma Pharmaceuticals PLC | $4.5B | 11.7 | 31.4 | 21.7 | 12.9 | 14.3 | 7 | BEARISH | -7.1 |
| MBX MBX Biosciences, Inc. Common Stock | $2.8B | -24.4 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 226.9 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 128.1 | 61.3 | 282.5 | 14.6 | 7.2 | 5 | BEARISH | 19.0 |
| AVBP ArriVent BioPharma, Inc. | $1.3B | -7.7 | -53.1 | 2345.1 | — | — | 3 | BEARISH | 53.1 |
| OMDA Omada Health | $1.2B | 300.0 | 1.8 | -1.5 | 6.0 | 404.7 | 7 | BEARISH | -9.2 |
| SLNCF Silence Therapeutics plc | $570M | -2.8 | -90.4 | 137.0 | — | -97.6 | 1 | BEARISH | 175.9 |
| ZRSEF DocMorris AG | $500M | -8.1 | -65.3 | -43.0 | -8.9 | -0.4 | 4 | BEARISH | 0.0 |
| AVIR Atea Pharmaceuticals, Inc. | $410M | -2.5 | -58.1 | 974.6 | — | — | 3 | BEARISH | 78.1 |
| CARL Carlsmed, Inc. | $390M | -10.5 | -43.8 | -122.7 | -55.5 | — | 2 | BEARISH | 7.1 |
| PCVX Vaxcyte, Inc. | $8.2B | -7.4 | -36.5 | -66.4 | — | — | 0 | BEARISH | 48.5 |
| GNGBY Getinge AB (publ) | $6.7B | 25.1 | 8.9 | 8.0 | 10.0 | -3.9 | 8 | BEARISH | 11.1 |
| ZLAB Zai Lab Limited | $2.8B | -14.4 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | BEARISH | -29.4 |
| NAMSW NewAmsterdam Pharma Company N.V. | $2.7B | -10.6 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -26.1 |
| PANHF Ping An Healthcare and Technology Company Limited | $1.7B | 23.9 | 5.3 | 6.9 | 8.8 | 4.4 | 7 | BEARISH | -56.5 |
| ARDT Ardent Health Inc. | $1.5B | 18.8 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BEARISH | -20.9 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.3B | -9.0 | -39.8 | -102.9 | — | — | 3 | BEARISH | 4.3 |
| ANGO AngioDynamics, Inc. | $620M | -17.2 | -20.8 | -27.0 | -13.2 | 9.5 | 4 | BEARISH | 36.5 |
| DCTH Delcath Systems, Inc. | $520M | 1375.5 | 0.5 | -2.7 | 9.2 | 35.8 | 6 | BEARISH | 40.7 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -83.2 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | BEARISH | -14.8 |
| MDRSF Medartis Holding AG | $1.4B | 68.4 | 5.2 | 3.9 | 3.2 | 29.8 | 7 | BEARISH | 72.5 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $980M | 13.9 | 1.4 | -0.8 | 3.9 | -17.8 | 5 | BEARISH | -7.5 |
| IRD Opus Genetics, Inc. | $380M | -3.6 | -4796.5 | 59.8 | -1072.6 | -36.1 | 3 | BEARISH | 154.4 |
| CVSGF CVS Group plc | $1.1B | 45.6 | 16.0 | 17.2 | 2.7 | 49.6 | 6 | BEARISH | 1.8 |
| PHGUF Pharming Group N.V. | $780M | 66.6 | 3.7 | 5.8 | 1.7 | 7.8 | 7 | BEARISH | -26.0 |
| OFIX Orthofix Medical Inc. | $370M | -5.9 | -13.9 | -3.6 | -7.5 | 3.0 | 6 | BEARISH | -36.6 |
| VHIBF Vitalhub Corp. | $340M | 63.2 | 3.3 | 10.7 | 6.1 | 53.9 | 7 | BEARISH | -32.0 |
| CATX Perspective Therapeutics, Inc. | $310M | -1.8 | -39.5 | -108.8 | -33069.1 | -35.3 | 3 | BEARISH | -19.8 |
| ALBHF Alibaba Health Information Technology Limited | $5.8B | 20.2 | 17.6 | 33.4 | 3.8 | 2.9 | 5 | BEARISH | -57.5 |
| ERAS Erasca, Inc. | $5.1B | -15.5 | -78.2 | -87.5 | — | — | 2 | BEARISH | 567.0 |
| ICUI ICU Medical, Inc. | $4.0B | 132.8 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BEARISH | 31.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -2.9 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | BEARISH | 27.9 |
| ETON Eton Pharmaceuticals, Inc. | $1.5B | 119.1 | 36.0 | 33.3 | 30.8 | 81.5 | 7 | BEARISH | 173.2 |
| HCSG Healthcare Services Group, Inc. | $1.4B | 12.1 | 24.7 | 31.7 | 4.8 | 5.2 | 8 | BEARISH | 28.4 |
| SGP SpyGlass Pharma, Inc. Common Stock | $830M | — | — | — | — | — | — | BEARISH | — |
| ACHV Achieve Life Sciences, Inc. | $740M | -4.7 | -845.0 | 24.6 | — | — | 2 | BEARISH | 133.6 |
| PTKFF PT Kalbe Farma Tbk. | $2.4B | 9.1 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | BEARISH | -16.3 |
| ULIHF The United Laboratories International Holdings Limited | $2.1B | 23.4 | 23.4 | 27.9 | 5.6 | -4.4 | 4 | BEARISH | -52.6 |
| JXFGF Jinxin Fertility Group Limited | $740M | 25.5 | -8.2 | 3.3 | 7.8 | -2.0 | 5 | BEARISH | 3.6 |
| VBIZF Viva Biotech Holdings | $400M | 15.5 | 9.0 | 8.9 | 8.0 | -15.5 | 5 | BEARISH | -31.6 |
| EXETF Extendicare Inc. | $1.9B | 21.4 | 43.8 | 14.1 | 5.0 | 31.2 | 3 | BEARISH | 84.2 |
| MRCHF H.U. Group Holdings, Inc. | $1.2B | 20.0 | 5.0 | 2.3 | 2.0 | 2.3 | 9 | BEARISH | -11.6 |
| CSBTF Kuros Biosciences AG | $950M | 102.9 | 2.4 | 3.5 | 4.8 | 236.5 | 4 | BEARISH | -15.2 |
| AVCTF Avacta Group Plc | $440M | -7.9 | -553.3 | -1587.8 | -33970.3 | -65.3 | 2 | BEARISH | 25.6 |
| HNSBF Hansa Biopharma AB | $330M | -4.2 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | 9.7 |
| LYPHF Luye Pharma Group Ltd. | $1.1B | 9.1 | 7.6 | 13.0 | 13.0 | -1.2 | 4 | BEARISH | 0.8 |
| BEAM Beam Therapeutics Inc. | $2.5B | -29.9 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BEARISH | 1.5 |
| LMAT LeMaitre Vascular, Inc. | $1.8B | 27.2 | 16.8 | 25.6 | 24.2 | 11.8 | 8 | BEARISH | -8.7 |
| CNMD CONMED Corporation | $1.4B | 25.0 | 5.5 | 5.2 | 6.7 | 3.4 | 7 | BEARISH | -1.8 |
| RAFLF Raffles Medical Group Ltd | $1.2B | 22.4 | 5.8 | 7.3 | 8.2 | -2.8 | 7 | BEARISH | -20.0 |
| TNDM Tandem Diabetes Care, Inc. | $1.1B | -17.8 | -48.0 | -8.2 | -8.3 | -7.1 | 4 | BEARISH | 33.0 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.3 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | BEARISH | -28.6 |
| IUSDF AS ONE Corporation | $1.0B | 18.0 | 12.2 | 13.4 | 8.1 | 5.7 | 6 | BEARISH | -40.4 |
| TDVXF Tobii Dynavox AB (publ) | $790M | 36.5 | 37.3 | 16.1 | 11.0 | 12.6 | 8 | BEARISH | -41.6 |
| COLL Collegium Pharmaceutical, Inc. | $710M | 14.4 | 17.6 | 9.4 | -7.5 | 14.3 | 6 | BEARISH | -37.4 |
| SMSZF SMS Co., Ltd. | $700M | -14.6 | -38.9 | 25.5 | -109.1 | 6.8 | 4 | BEARISH | 0.0 |
| TGRNF Tong Ren Tang Technologies Co. Ltd. | $510M | 11.1 | 10.2 | 30.0 | 8.2 | -8.5 | 6 | BEARISH | -43.0 |
| RGEDF Gedeon Richter PLC | $7.0B | 9.7 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | BEARISH | 32.3 |
| KNSA Kiniksa Pharmaceuticals International, plc | $5.8B | 70.8 | 14.0 | 51.6 | 10.4 | 58.9 | 7 | BEARISH | 96.1 |
| STVN Stevanato Group S.p.A. | $5.5B | 37.4 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -23.2 |
| SNDA Sonida Senior Living, Inc. | $1.8B | -5.4 | -25.2 | -2.9 | -11.8 | 49.4 | 4 | BEARISH | 36.5 |
| SGRY Surgery Partners, Inc. | $1.7B | -19.3 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BEARISH | -37.1 |
| GDRX GoodRx Holdings, Inc. | $1.1B | 62.4 | 2.5 | 3.5 | 4.3 | -1.8 | 6 | BEARISH | -34.8 |
| IART Integra LifeSciences Holdings Corporation | $990M | -137.5 | -0.7 | 18.4 | 1.1 | 1.6 | 6 | BEARISH | -13.9 |
| CBIO Crescent Biopharma, Inc. | $530M | -1.9 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 20.3 |
| CERS Cerus Corporation | $460M | -63.0 | -10.8 | -7.4 | -5.1 | 15.1 | 5 | BEARISH | 50.0 |
| NRC NRC Health | $460M | 77.5 | 42.0 | 9.9 | -9.3 | -0.2 | 6 | BEARISH | 33.4 |
| NIKA Nika Pharmaceuticals Inc. | $430M | -5519.3 | 26.8 | 18.5 | — | 100.0 | 3 | BEARISH | 40.6 |
| EDIT Editas Medicine, Inc. | $400M | -3.5 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BEARISH | -26.2 |
| SKHCF Sonic Healthcare Limited | $6.4B | 15.0 | 13.8 | 22.2 | 6.2 | 21.4 | 5 | BEARISH | -12.3 |
| FGHQF Frontage Holdings Corporation | $350M | 28.9 | 4.2 | 4.5 | 4.6 | 2.1 | 6 | BEARISH | 16.8 |
| DFTX Definium Therapeutics, Inc. | $5.0B | -10.9 | -25.7 | 82.4 | — | — | 2 | BEARISH | — |
| LQDA Liquidia Corporation | $2.5B | 18.3 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BEARISH | 29.9 |
| GHRS GH Research PLC | $1.6B | -22.9 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 69.0 |
| LXRX Lexicon Pharmaceuticals, Inc. | $810M | -12.1 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 59.6 |
| ACRS Aclaris Therapeutics, Inc. | $610M | -7.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | BEARISH | 134.8 |
| LEGN Legend Biotech Corporation | $3.4B | -37.1 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BEARISH | -43.1 |
| HSIC Henry Schein, Inc. | $9.7B | 24.5 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | BEARISH | 29.4 |
| PODD Insulet Corp. | $9.1B | 24.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BEARISH | -57.0 |
| CHE Chemed Corporation | $6.6B | 25.5 | 27.1 | 23.2 | 10.1 | 3.3 | 6 | BEARISH | 15.3 |
| BLCO Bausch + Lomb Corporation | $6.1B | -35.8 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BEARISH | 16.6 |
| GALNF Galenica AG | $4.9B | 25.5 | 25.0 | 19.2 | 3.1 | 7.5 | 5 | BEARISH | 30.6 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.6 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | BEARISH | 8.6 |
| LFTSF LifeTech Scientific Corporation | $1.0B | 88.1 | 7.3 | 6.9 | -5.7 | 9.2 | 4 | BEARISH | 0.0 |
| ENOV Enovis Corporation | $1.0B | -0.9 | -54.3 | -13.5 | -0.2 | 4.9 | 4 | BEARISH | -41.7 |
| IMTX Immatics N.V. | $1.0B | -4.2 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -15.7 |
| ODTX Odyssey Therapeutics, Inc. | $1.0B | — | — | — | — | — | — | BEARISH | — |
| SVRA Savara Inc. | $990M | -8.3 | -105.5 | -15438.9 | — | — | 2 | BEARISH | 35.9 |
| DSGN Design Therapeutics, Inc. | $770M | -10.5 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 81.7 |
| MTLZF Metall Zug AG | $680M | -36.4 | -5.8 | -4.7 | -5.6 | -60.7 | 4 | BEARISH | 0.0 |
| CRWRF Craneware plc | $620M | 24.1 | 11.2 | 12.9 | 9.7 | 8.7 | 7 | BEARISH | -47.1 |
| RZLT Rezolute, Inc. | $390M | -5.3 | -59.0 | 1060.6 | — | — | 2 | BEARISH | -57.5 |
| OCGN Ocugen, Inc. | $350M | -4.0 | 1211.7 | 190.2 | -1671.8 | -3.7 | 2 | BEARISH | -39.3 |
| TLPPF Telix Pharmaceuticals Limited | $3.6B | 109.7 | 14.8 | 5.8 | 8.0 | 201.7 | 5 | BEARISH | 15.3 |
| IDYA IDEAYA Biosciences, Inc. | $3.5B | -19.5 | -16.2 | -42.9 | -1269.6 | 3244.7 | 3 | BEARISH | 36.5 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.0B | 6.7 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BEARISH | 38.9 |
| SEPN Septerna Inc | $1.7B | -69.8 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BEARISH | 98.5 |
| CRON Cronos Group Inc. | $1.2B | 17.2 | 6.5 | 5.3 | 45.4 | 86.4 | 6 | BEARISH | 21.4 |
| SIBN SI-BONE, Inc. | $800M | -53.2 | -8.3 | -32.2 | -7.3 | 15.3 | 6 | BEARISH | 26.7 |
| FDMT 4D Molecular Therapeutics, Inc. | $710M | -5.0 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | BEARISH | 56.6 |
| NVST Envista Holdings Corp | $3.8B | 39.8 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | BEARISH | 15.3 |
| DNLI Denali Therapeutics Inc. | $3.2B | -7.0 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 34.1 |
| JNDOF JINS HOLDINGS Inc. | $900M | 15.6 | 25.4 | 27.3 | 9.4 | 15.5 | 4 | BEARISH | 68.9 |
| NWPHF Newron Pharmaceuticals S.p.A. | $420M | -6.0 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| PLSE Pulse Biosciences, Inc. | $3.3B | -40.9 | -78.5 | -1410.2 | -5681.3 | — | 3 | BEARISH | 164.3 |
| ARCT Arcturus Therapeutics Holdings Inc. | $370M | -3.9 | -46.3 | -2501.0 | -803.8 | -79.1 | 1 | BEARISH | -36.4 |
| QDEL QuidelOrtho Corporation | $730M | -0.7 | -45.9 | -13.7 | -14.7 | 0.1 | 4 | BEARISH | -65.5 |
| MOH Molina Healthcare, Inc. | $9.9B | 1184.6 | -0.2 | -29.6 | 0.6 | 2.6 | 6 | BEARISH | -1.7 |
| IMVT Immunovant, Inc. | $6.9B | -11.9 | -64.8 | 851.4 | — | — | 2 | BEARISH | 105.8 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.7 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | BEARISH | 93.6 |
| CGON CG Oncology Inc. | $5.9B | -25.0 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | BEARISH | 70.8 |
| RDNT RadNet, Inc. | $5.5B | -262.4 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BEARISH | -10.3 |
| ORKA Oruka Therapeutics, Inc. | $5.1B | -34.2 | -18.2 | -50.3 | — | — | 4 | BEARISH | 353.9 |
| LFST LifeStance Health Group, Inc. | $4.6B | 90.9 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BEARISH | 117.1 |
| EWTX Edgewise Therapeutics, Inc. | $4.5B | -22.4 | -38.0 | 1912.5 | — | — | 1 | BEARISH | 168.1 |
| RCUS Arcus Biosciences, Inc. | $3.1B | -6.2 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | 81.5 |
| TMDX TransMedics Group, Inc. | $2.8B | 18.1 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -30.5 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.5 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| CLDX Celldex Therapeutics, Inc. | $2.1B | -7.3 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 25.1 |
| URGN UroGen Pharma Ltd. | $2.0B | -20.9 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 132.3 |
| BHVN Biohaven Ltd. | $1.9B | -2.8 | -799.5 | -1083.0 | — | — | 3 | BEARISH | -13.1 |
| RTEZ Rest Ez Inc. | $1.9B | — | — | — | — | — | — | BEARISH | 0.0 |
| PVLA Palvella Therapeutics, Inc. | $1.9B | -27.4 | -46.6 | 137.5 | — | — | 3 | BEARISH | 109.5 |
| NVCR Novocure Ltd | $1.7B | -11.5 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 6.9 |
| AGL Agilon Health, Inc. | $1.4B | -5.5 | -78.9 | -273.7 | 1.2 | 0.3 | 6 | BEARISH | 237.0 |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.5 | -45.3 | -2390.9 | — | — | 2 | BEARISH | 52.2 |
| INNV Innovage Holding Corp. | $1.2B | -432.9 | -1.1 | -89.6 | 3.2 | 16.4 | 6 | BEARISH | 72.6 |
| VOR Vor Biopharma Inc. | $1.0B | -0.1 | -73.6 | 22.2 | — | — | 3 | BEARISH | -52.4 |
| ABUS Arbutus Biopharma Corp | $880M | 5.6 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -3.0 |
| SLBT SL Science Holding Ltd | $880M | — | — | — | — | — | — | BEARISH | — |
| AVR Anteris Technologies Global Corp. | $750M | -2.8 | -75.1 | 3136.2 | -2884.3 | 31.1 | 5 | BEARISH | 81.4 |
| IRWD Ironwood Pharmaceuticals, Inc. | $600M | 4.6 | -55.3 | 93.9 | 45.4 | 26.2 | 7 | BEARISH | 149.3 |
| RSLBF RaySearch Laboratories AB (publ) | $560M | 29.1 | 26.1 | 21.8 | 7.2 | 1.2 | 6 | BEARISH | -40.2 |
| EIKN Eikon Therapeutics, Inc. Common Stock | $400M | — | — | — | — | — | — | BEARISH | — |
| VREOF Vireo Growth Inc. | $360M | -4.8 | -4.6 | -0.7 | -0.0 | — | 3 | BEARISH | — |
| PRAX Praxis Precision Medicines, Inc. | $8.2B | -22.8 | -38.9 | -51.2 | — | -100.0 | 4 | BEARISH | 457.4 |
| CYTK Cytokinetics, Incorporated | $8.2B | -9.1 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 17.5 |
| HQY HealthEquity, Inc. | $7.5B | 32.2 | 10.2 | 9.0 | 14.9 | 9.5 | 9 | BEARISH | -0.7 |
| ALKS Alkermes plc | $7.0B | 103.6 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BEARISH | 36.2 |
| SRRK Scholar Rock Holding Corporation | $5.6B | -14.1 | -167.8 | 931.3 | — | — | 2 | BEARISH | 35.0 |
| TFX Teleflex Incorporated | $5.5B | -5.3 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BEARISH | 0.5 |
| DNTH Dianthus Therapeutics, Inc. | $4.9B | -678.5 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | BEARISH | 126.6 |
| XENE Xenon Pharmaceuticals Inc. | $3.7B | -8.0 | -43.6 | -109.7 | — | -100.0 | 3 | BEARISH | -2.8 |
| ELVN Enliven Therapeutics, Inc. | $3.4B | -28.6 | -15.3 | -6535.0 | — | — | 3 | BEARISH | 136.9 |
| VRBCF Virbac S.A. | $3.2B | 16.6 | 26.1 | 25.2 | 11.4 | 14.6 | 7 | BEARISH | 10.8 |
| ALFRY Alfresa Holdings Corporation | $2.5B | 10.3 | 8.6 | 7.0 | 1.3 | 6.3 | 7 | BEARISH | -16.7 |
| ORPEF emeis Société anonyme | $2.3B | -4.5 | -38.4 | 2.8 | -5.4 | 2.2 | 5 | BEARISH | 0.0 |
| PGNY Progyny, Inc. | $2.0B | 26.0 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BEARISH | 18.9 |
| ESTA Establishment Labs Holdings Inc. | $1.9B | -49.0 | -175.3 | -6.9 | -17.4 | 38.6 | 5 | BEARISH | 56.9 |
| ELEAF EL.En. S.p.A. | $1.4B | 14.1 | 13.2 | 29.1 | 6.0 | 25.8 | 8 | BEARISH | 39.8 |
| IDRSF Idorsia Ltd | $1.4B | -3.4 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 17.0 |
| MEDOF Medios AG | $1.3B | 23.5 | 2.1 | 2.8 | 0.6 | 10.0 | 6 | BEARISH | 0.0 |
| CGEM Cullinan Therapeutics, Inc. | $950M | -4.6 | -50.3 | 1635.6 | — | — | 1 | BEARISH | 158.5 |
| JBIO Jade Biosciences, Inc. | $860M | -5.1 | -47.8 | 629.9 | — | — | 3 | BEARISH | 55.0 |
| INMD InMode Ltd. | $810M | 11.3 | 12.3 | 44.5 | 17.9 | -6.7 | 5 | BEARISH | -7.8 |
| MNPR Monopar Therapeutics Inc. | $520M | -33.3 | -19.5 | 523.8 | — | — | 2 | BEARISH | -8.0 |
| ASMB Assembly Biosciences, Inc. | $450M | 41.0 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -8.4 |
| CTEV Claritev Corporation | $400M | -1.4 | 169.3 | 0.9 | -23.0 | 110.3 | 4 | BEARISH | -51.2 |
| HELP Cybin Inc. Common Stock | $730M | -2.8 | -38.6 | -94.5 | — | — | 2 | BEARISH | — |
| AKBLF ALK-Abelló A/S | $6.2B | 33.0 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BEARISH | 7.1 |
| SHTDF Sinopharm Group Co. Ltd. | $5.8B | 5.6 | 17.2 | 15.0 | 1.2 | 9.8 | 6 | BEARISH | -16.9 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.5B | -22.1 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | BEARISH | -11.8 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.6B | -7.0 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 12.2 |
| HBMHF HBM Holdings Limited | $1.3B | 17.0 | 58.2 | 96.1 | 53.0 | 133.3 | 6 | BEARISH | -8.8 |
| ARDX Ardelyx, Inc. | $830M | -14.8 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -37.7 |
| PHR Phreesia, Inc. | $620M | 58.5 | 0.8 | -1.4 | 1.0 | 14.5 | 4 | BEARISH | -55.1 |
| SWDCF Swedencare AB (publ) | $370M | 43.2 | 1.1 | 1.6 | 3.5 | 4.5 | 8 | BEARISH | -35.8 |
| MOBI Mobia Medical, Inc. Common Stock | $310M | — | — | — | — | — | — | BEARISH | — |
| KRYS Krystal Biotech, Inc. | $9.5B | 39.0 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 79.4 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.0 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | BEARISH | 118.8 |
| KYMR Kymera Therapeutics, Inc. | $8.8B | -33.0 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BEARISH | 96.5 |
| BLTE Belite Bio, Inc | $6.4B | -57.8 | -20.8 | -11.5 | — | — | 3 | BEARISH | 117.1 |
| SHC Sotera Health Company | $5.2B | 31.8 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | BEARISH | 12.5 |
| MMSI Merit Medical Systems, Inc. | $5.1B | 34.8 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BEARISH | 4.0 |
| LIVN LivaNova PLC | $4.1B | 21.8 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BEARISH | 48.3 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.1B | -67.0 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 27.3 |
| ACHC Acadia Healthcare Company, Inc. | $2.6B | -2.3 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | BEARISH | 14.3 |
| NRIX Nurix Therapeutics, Inc. | $2.4B | -6.7 | -80.3 | -1655.0 | -990.1 | -58.4 | 2 | BEARISH | 144.6 |
| PHVS Pharvaris N.V. | $2.2B | -10.3 | -70.7 | 860.9 | — | — | 4 | BEARISH | 29.6 |
| BCRX BioCryst Pharmaceuticals, Inc. | $2.1B | -5.7 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | BEARISH | 10.8 |
| ADUS Addus HomeCare Corporation | $2.1B | 19.6 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BEARISH | -4.0 |
| AXGN AxoGen, Inc. | $2.0B | -55.4 | -18.2 | -5.6 | -2.2 | 23.6 | 4 | BEARISH | 109.2 |
| AGIO Agios Pharmaceuticals, Inc. | $1.9B | -4.5 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BEARISH | -20.6 |
| ZYME Zymeworks Inc. | $1.9B | -12.5 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BEARISH | 48.5 |
| NUVB Nuvation Bio Inc. | $1.8B | -11.8 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | 38.6 |
| CMPS COMPASS Pathways plc | $1.6B | -2.1 | -319.1 | 48.8 | — | — | 2 | BEARISH | 106.2 |
| IMCR Immunocore Holdings plc | $1.5B | -164.8 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BEARISH | -17.3 |
| TSHA Taysha Gene Therapies, Inc. | $1.5B | -11.0 | -47.1 | 961.0 | — | -32.3 | 3 | BEARISH | 45.6 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -10.9 | -1773.6 | 55.8 | — | -100.0 | 4 | BEARISH | 185.4 |
| NBTX Nanobiotix S.A. | $1.3B | -20.8 | 380.7 | 158.8 | -941.2 | -73.7 | 3 | BEARISH | 37.4 |
| TDOC Teladoc Health, Inc. | $1.0B | -5.6 | -13.0 | -8.7 | -6.4 | -2.1 | 5 | BEARISH | -29.2 |
| KURA Kura Oncology, Inc. | $950M | -3.2 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BEARISH | 15.8 |
| CADL Candel Therapeutics, Inc. | $750M | -7.2 | -81.8 | 219.4 | — | — | 2 | BEARISH | 83.8 |
| ZVRA Zevra Therapeutics, Inc. | $590M | 10.4 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | 5.9 |
| AQST Aquestive Therapeutics, Inc. | $570M | -7.0 | 121.1 | 43.4 | -165.5 | 22.6 | 5 | BEARISH | -22.6 |
| PRME Prime Medicine, Inc. | $540M | -2.7 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BEARISH | -46.7 |
| AUTL Autolus Therapeutics plc | $470M | -1.7 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | 6.6 |
| EOLS Evolus, Inc. | $470M | -13.8 | 138.6 | -20.7 | -9.6 | 13.9 | 5 | BEARISH | 16.1 |
| OVID Ovid Therapeutics Inc. | $440M | -5.0 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | BEARISH | 73.7 |
| NGNE Neurogene Inc. | $410M | -4.7 | -45.3 | -111469.0 | — | — | 2 | BEARISH | 42.7 |
| CLPT ClearPoint Neuro, Inc. | $330M | -9.2 | -226.5 | -54.1 | -104.2 | 25.9 | 3 | BEARISH | -47.9 |
| CCCC C4 Therapeutics, Inc. | $330M | -3.0 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | BEARISH | 37.2 |
| AXSM Axsome Therapeutics, Inc. | $9.2B | -47.8 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 51.2 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $9.0B | -28.7 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 83.3 |
| ATR AptarGroup, Inc. | $7.7B | 21.4 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BEARISH | -10.2 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.4B | -29.8 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | BEARISH | -7.2 |
| YPHDF Ypsomed Holding AG | $5.7B | 21.9 | 40.4 | 23.5 | 22.5 | 51.4 | 8 | BEARISH | -8.1 |
| REGMF RemeGen Co., Ltd. | $5.6B | 11.3 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | 96.8 |
| TVTX Travere Therapeutics, Inc. | $5.3B | -126.5 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 129.7 |
| DSRLF DiaSorin S.p.A. | $4.2B | 23.3 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BEARISH | -10.9 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 8.9 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | BEARISH | -6.1 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.1B | -19.7 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 98.5 |
| DYN Dyne Therapeutics, Inc. | $2.8B | -4.6 | -81.6 | 240.4 | — | — | 2 | BEARISH | 21.6 |
| MEDGF Medacta Group S.A. | $2.7B | 31.2 | 41.7 | 21.5 | 11.4 | 31.6 | 5 | BEARISH | 63.9 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.7B | 9.5 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BEARISH | 40.2 |
| IRON Disc Medicine, Inc. | $2.5B | -9.8 | -39.1 | 1672.3 | — | — | 1 | BEARISH | -3.8 |
| WGS GeneDx Holdings Corp. | $2.2B | -20.1 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -35.6 |
| IMNM Immunome, Inc. | $2.0B | -8.2 | -64.0 | -2208.4 | — | -100.0 | 4 | BEARISH | 84.3 |
| TRVI Trevi Therapeutics, Inc. | $2.0B | -41.2 | -19.7 | -1451.7 | — | — | 3 | BEARISH | 48.0 |
| QURE uniQure N.V. | $1.6B | -5.8 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | BEARISH | -57.3 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.5B | -10.6 | -40.0 | 3981.5 | — | — | 4 | BEARISH | 12.2 |
| OCUL Ocular Therapeutix, Inc. | $1.5B | -4.9 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -37.0 |
| ANAB AnaptysBio, Inc. | $1.4B | 7.2 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | BEARISH | 127.7 |
| TWAPF Towa Pharmaceutical Co., Ltd. | $1.3B | 20.8 | 3.0 | 2.6 | -17.0 | 6.0 | 5 | BEARISH | inf |
| NKTR Nektar Therapeutics | $1.2B | -6.5 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -25.9 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.2B | -5.7 | -41.0 | 583.9 | — | — | 2 | BEARISH | 6.1 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.1B | -12.5 | -25.8 | -768.9 | — | — | 2 | BEARISH | 134.7 |
| MGTX MeiraGTx Holdings plc | $1.0B | 14.2 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 30.5 |
| AKTS Aktis Oncology, Inc. | $990M | -17.6 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 18875.4 |
| ANRO Alto Neuroscience, Inc. | $870M | -10.0 | -49.2 | -201.4 | — | — | 3 | BEARISH | 509.6 |
| AVTX Avalo Therapeutics, Inc. | $790M | -3.2 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | 15.7 |
| XVIPF Xvivo Perfusion AB (publ) | $690M | 76.0 | 7.6 | 35.3 | 6.8 | 8.3 | 6 | BEARISH | 14.4 |
| SLDB Solid Biosciences Inc. | $670M | -3.6 | -65.5 | -1012.6 | — | — | 3 | BEARISH | 16.7 |
| CLYM Climb Bio, Inc. | $630M | -13.2 | -27.1 | -88.6 | — | — | 2 | BEARISH | 455.3 |
| AURA Aura Biosciences, Inc. | $630M | -3.4 | -53.5 | -1360.0 | — | — | 4 | BEARISH | -1.0 |
| IMMX Immix Biopharma, Inc. | $530M | -11.0 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 365.4 |
| BRSYF BrainsWay Ltd. | $510M | 52.6 | 12.9 | 30.9 | 15.8 | 31.5 | 6 | BEARISH | 129.5 |
| TECX Tectonic Therapeutic, Inc. | $430M | -4.9 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 43.9 |
| SRTA Strata Critical Medical, Inc. | $410M | 9.5 | 16.0 | -6.2 | -14.5 | 0.6 | 3 | BEARISH | -8.1 |
| EVH Evolent Health, Inc. | $390M | -0.8 | -79.0 | -1.8 | -4.3 | -4.5 | 5 | BEARISH | -56.8 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -78.5 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | BEARISH | 6.4 |
| ARTV Artiva Biotherapeutics, Inc. | $330M | -2.1 | -36.6 | -954.6 | — | — | 3 | BEARISH | 133.9 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BEARISH | — |
| APMD Apnimed, Inc. | $860M | — | — | — | — | — | — | BEARISH | — |
| CHEOF Cochlear Limited | $6.1B | 55.7 | 30.0 | 34.3 | -1.2 | 11.5 | 6 | BEARISH | -47.4 |
| PTCT PTC Therapeutics, Inc. | $5.3B | -129.5 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | BEARISH | 2.3 |
| CAMRF Camurus AB | $3.7B | 53.4 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| IRTC iRhythm Technologies, Inc. | $3.6B | -256.7 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BEARISH | -34.1 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 15.9 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| OPCH Option Care Health, Inc. | $3.4B | 17.0 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BEARISH | -16.9 |
| AMFPF Amplifon S.p.A. | $3.0B | 39.7 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -30.4 |
| ZLDPF Zealand Pharma A/S | $2.8B | 6.8 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -47.9 |
| BKD Brookdale Senior Living Inc. | $2.6B | -18.8 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 27.0 |
| VERA Vera Therapeutics, Inc. | $2.2B | -5.2 | -91.8 | 2030.6 | — | — | 1 | BEARISH | 5.7 |
| PBH Prestige Consumer Healthcare Inc. | $2.1B | 12.6 | 10.2 | 8.0 | 19.1 | -4.3 | 5 | BEARISH | -28.5 |
| GENSF Genus plc | $1.9B | 5.0 | 45.8 | 14.4 | 80.4 | 28.9 | 7 | BEARISH | -17.7 |
| ADDLF AddLife AB (publ) | $1.9B | 34.7 | 11.4 | 7.4 | 4.8 | 2.5 | 7 | BEARISH | -62.5 |
| ALHC Alignment Healthcare, Inc. | $1.6B | 39.8 | 20.0 | -54.4 | 2.7 | 37.2 | 8 | BEARISH | -52.8 |
| MCRPF MicroPort Scientific Corp. | $1.6B | 31.2 | -19.0 | -7.8 | 21.3 | 13.2 | 4 | BEARISH | -54.0 |
| VIMGF Vimian Group AB (publ) | $1.5B | 44.8 | 5.2 | 5.9 | 6.9 | 10.8 | 6 | BEARISH | -8.0 |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.4B | — | — | — | — | — | — | BEARISH | — |
| LWSCF Sienna Senior Living Inc. | $1.4B | 38.5 | 6.7 | 3.9 | 4.4 | 16.2 | 7 | BEARISH | 4.2 |
| KLRA Kailera Therapeutics, Inc. | $1.4B | — | — | — | — | — | — | BEARISH | — |
| KARD Kardigan, Inc. | $1.3B | — | — | — | — | — | — | BEARISH | — |
| VTRLY Vitrolife AB (publ) | $1.3B | -2.5 | -46.5 | -42.3 | 15.1 | -4.6 | 6 | BEARISH | -36.7 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.2B | — | — | — | — | — | — | BEARISH | — |
| RYHTY Ryman Healthcare Limited | $1.2B | -11.0 | -14.4 | -0.6 | -30.8 | 24.7 | 4 | BEARISH | -14.1 |
| TTALF Terveystalo Oyj | $1.1B | 13.7 | 12.6 | 7.6 | 4.7 | -7.9 | 4 | BEARISH | -30.9 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $1.1B | 18.4 | 4.2 | -0.8 | 19.4 | 33.4 | 7 | BEARISH | 21.7 |
| CMOPF Cosmo Pharmaceuticals N.V. | $1.1B | -148.1 | 9.2 | 10.2 | -9.5 | -1.7 | 3 | BEARISH | -22.4 |
| LMRI Lumexa Imaging Holdings, Inc. Common Stock | $990M | -27.5 | -3.9 | 0.1 | 1.0 | — | 3 | BEARISH | — |
| SPTX Seaport Therapeutics, Inc. Common Stock | $990M | — | — | — | — | — | — | BEARISH | — |
| MLTX MoonLake Immunotherapeutics | $960M | -3.0 | -67.4 | 2902.7 | — | — | 1 | BEARISH | 61.6 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $820M | -5.1 | -5.9 | -0.3 | -14.3 | -30.1 | 5 | BEARISH | -40.7 |
| AHCO AdaptHealth Corp. | $760M | -3.3 | -15.5 | -0.2 | -18.1 | 22.9 | 6 | BEARISH | -38.5 |
| WVE Wave Life Sciences Ltd. | $740M | -3.5 | -68.3 | -2645.3 | -3052.6 | -30.4 | 5 | BEARISH | -46.2 |
| FTH Faeth Therapeutics, Inc. | $730M | — | — | — | — | — | — | BEARISH | — |
| GMRS GMR Solutions Inc. | $530M | — | — | — | — | — | — | BEARISH | — |
| DRUG Bright Minds Biosciences Inc. | $500M | -24.3 | -13.7 | -105758.3 | — | — | 3 | BEARISH | -12.5 |
| TCMD Tactile Systems Technology, Inc. | $500M | 20.3 | 11.9 | 13.8 | 9.1 | 17.2 | 8 | BEARISH | 59.8 |
| OCS Oculis Holding AG | $500M | -5.2 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -49.8 |
| KSRBF Kossan Rubber Industries Bhd | $480M | 15.4 | 5.0 | 8.5 | 11.3 | 1.0 | 5 | BEARISH | -43.2 |
| PRTA Prothena Corporation plc | $440M | -10.1 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | BEARISH | -15.7 |
| MPLT MapLight Therapeutics, Inc. | $420M | -1.9 | -57.5 | -366.6 | — | — | 2 | BEARISH | — |
| ZURA Zura Bio Limited | $390M | -3.6 | -54.3 | 910.3 | — | — | 2 | BEARISH | 1.7 |
| CABA Cabaletta Bio, Inc. | $330M | -1.3 | -93.2 | -1308.0 | — | — | 3 | BEARISH | -13.4 |
| BBOT BridgeBio Oncology Therapeutics Inc. | $310M | -0.0 | -56.4 | -157.3 | — | — | 1 | BEARISH | -67.7 |
| IONS Ionis Pharmaceuticals, Inc. | $7.2B | -12.6 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | BEARISH | -33.8 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 16.7 | 10.5 | 12.8 | 4.7 | 5.8 | 5 | BEARISH | inf |
| MMED MiniMed Group, Inc. Common Stock | $5.5B | — | — | — | — | — | — | BEARISH | — |
| COGT Cogent Biosciences, Inc. | $5.3B | -13.4 | -109.7 | 1964.0 | — | — | 3 | BEARISH | 119.5 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.1B | -5.7 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | BEARISH | 13.6 |
| CELC Celcuity Inc. | $3.5B | -16.8 | -1433.7 | 1325.2 | — | — | 3 | BEARISH | 59.4 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.3 | 11.3 | 10.9 | 3.5 | 5.6 | 5 | BEARISH | inf |
| VCRE Vicore Pharma Holding AB | $2.6B | — | — | — | — | — | — | BEARISH | — |
| VRDN Viridian Therapeutics, Inc. | $2.2B | -5.5 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BEARISH | -8.8 |
| MLYS Mineralys Therapeutics, Inc. | $2.1B | -5.6 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -40.6 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -12.2 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BEARISH | -9.4 |
| MESO Mesoblast Limited | $1.8B | -32.0 | -9.9 | -6.3 | -25.2 | 599.2 | 5 | BEARISH | -13.5 |
| GENB Generate Biomedicines, Inc. | $1.8B | -12.9 | -28.2 | -175.0 | -1065.2 | — | 1 | BEARISH | — |
| XRAY DENTSPLY SIRONA Inc. | $1.7B | -3.2 | -33.0 | 9.9 | 4.1 | -0.8 | 5 | BEARISH | -33.0 |
| GPCR Structure Therapeutics Inc. | $1.6B | -9.1 | -20.2 | -1134.3 | — | — | 3 | BEARISH | 6.3 |
| NPNKF Nippon Shinyaku Co., Ltd. | $1.6B | 7.2 | 11.1 | 12.2 | 8.9 | 7.1 | 3 | BEARISH | inf |
| INVA Innoviva, Inc. | $1.5B | 4.2 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | BEARISH | 12.8 |
| GTBIF Green Thumb Industries Inc. | $1.4B | 12.3 | 7.0 | 2.5 | 1.6 | 4.8 | 7 | BEARISH | -21.6 |
| ASPHF Ascentage Pharma Group International | $1.4B | -6.4 | -316.9 | -211.0 | -270.2 | -29.1 | 1 | BEARISH | -58.3 |
| SWGHF Sawai Group Holdings Co., Ltd. | $1.3B | 21.1 | 5.9 | 6.5 | -0.7 | 7.2 | 6 | BEARISH | -1.6 |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BEARISH | — |
| TRAX First Tracks Biotherapeutics Inc | $1.2B | — | — | — | — | — | — | BEARISH | — |
| TGLVY Top Glove Corporation Bhd. | $1.2B | 32.3 | 4.0 | 4.2 | 7.4 | 12.8 | 7 | BEARISH | 24.7 |
| HROW Harrow Health, Inc. | $1.1B | -30.7 | -114.8 | 1.9 | -24.4 | 21.1 | 5 | BEARISH | -37.0 |
| ASCLF Ascletis Pharma Inc. | $1.1B | -11.8 | -38.0 | -12387.1 | — | -95.5 | 2 | BEARISH | -14.8 |
| AORT Artivion, Inc. | $1.1B | -374.3 | -0.7 | -3.4 | -10.7 | 16.4 | 4 | BEARISH | -45.7 |
| EBOSY EBOS Group Limited | $1.0B | 14.2 | 11.3 | 9.3 | 1.7 | 3.6 | 4 | BEARISH | -53.6 |
| GRRMF Gerresheimer AG | $1.0B | -2.4 | 1.6 | 2.2 | -2.3 | 11.8 | 4 | BEARISH | -43.5 |
| PRCT PROCEPT BioRobotics Corporation | $980M | -8.8 | -30.2 | -47.6 | -28.4 | 22.7 | 2 | BEARISH | -50.6 |
| LTGO Latigo Biotherapeutics Inc. | $960M | — | — | — | — | — | — | BEARISH | — |
| CRVS Corvus Pharmaceuticals, Inc. | $920M | -17.0 | -35.4 | -415.6 | — | — | 4 | BEARISH | 50.1 |
| GLUE Monte Rosa Therapeutics, Inc. | $890M | -4.8 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | 40.0 |
| ALMS Alumis Inc. | $850M | -1.8 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | BEARISH | 68.7 |
| SANA Sana Biotechnology, Inc. | $800M | -3.8 | -152.9 | -242.3 | — | — | 3 | BEARISH | -21.9 |
| GERN Geron Corporation | $770M | -12.0 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -14.9 |
| IVEVF Inventiva S.A. | $760M | -5.9 | 5541.6 | 502.1 | -347346.6 | -57.3 | 4 | BEARISH | 41.2 |
| ATTO Attovia Therapeutics, Inc. | $740M | -18.5 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 308.8 |
| OLMA Olema Pharmaceuticals, Inc. | $720M | -3.9 | -52.7 | 585.3 | — | — | 2 | BEARISH | -25.4 |
| BLSM BlossomHill Therapeutics, Inc. | $570M | — | — | — | — | — | — | BEARISH | — |
| CTMX CytomX Therapeutics, Inc. | $560M | -5.7 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -23.6 |
| CRMD CorMedix Inc. | $560M | 3.0 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BEARISH | -34.9 |
| PHAT Phathom Pharmaceuticals, Inc. | $560M | -5.4 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -43.7 |
| ALT Altimmune, Inc. | $530M | -3.5 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -20.4 |
| SSII SS Innovations International, Inc. | $530M | -41.0 | -26.1 | -15.6 | -19.1 | 108.5 | 3 | BEARISH | -62.4 |
| ALLO Allogene Therapeutics, Inc. | $520M | -2.2 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 21.0 |
| ARVN Arvinas, Inc. | $480M | 39.0 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BEARISH | -18.8 |
| NPCE NeuroPace, Inc. | $430M | -22.2 | -122.1 | -39.6 | -27.2 | 11.6 | 4 | BEARISH | 25.2 |
| CALZF Polynovo Limited | $430M | 85.4 | 25.3 | 19.0 | 10.0 | 60.8 | 7 | BEARISH | -34.7 |
| GLAS Glass House Brands Inc | $420M | — | — | — | — | — | — | BEARISH | — |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $420M | — | — | — | — | — | — | BEARISH | — |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.9 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -59.7 |
| TLRY Tilray Brands, Inc. | $400M | -2.7 | -8.1 | -2.7 | -17.6 | 1.2 | 3 | BEARISH | -78.2 |
| VRNO Verano Holdings Corp | $390M | -1.5 | -4.5 | 1.5 | -6.2 | — | 3 | BEARISH | — |
| PTCHF PureTech Health plc | $380M | 8.2 | 14.7 | -97.5 | 1890.6 | -3.3 | 5 | BEARISH | -0.7 |
| KYTX Kyverna Therapeutics, Inc. | $380M | -2.1 | -87.2 | 14267.8 | — | — | 2 | BEARISH | 4.2 |
| CYH Community Health Systems, Inc. | $380M | -1.2 | 19.9 | -79.1 | 1.7 | 77.2 | 5 | BEARISH | -13.1 |
| RGNX REGENXBIO Inc. | $380M | -2.0 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -23.9 |
| RLMD Relmada Therapeutics, Inc. | $380M | -3.9 | -55.7 | 460.5 | — | — | 3 | BEARISH | 66.7 |
| CGC Canopy Growth Corporation | $370M | -1.9 | -53.8 | -16.5 | -220.5 | 27.6 | 2 | BEARISH | -36.6 |
| BNTC Benitec Biopharma Inc. | $310M | -9.2 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -29.6 |
| IDGXF Integrated Diagnostics Holdings plc | $310M | 11.0 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BEARISH | 11.2 |
| LRMR Larimar Therapeutics, Inc. | $310M | -1.5 | -139.6 | 590.9 | — | — | 2 | BEARISH | -28.7 |
| CUVL Clinuvel Pharmaceuticals Ltd. | $300M | — | — | — | — | — | — | BEARISH | — |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
CSTL vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F